A Prospective Multicenter Randomized Study State of Humoral Immunity after a New Coronavirus Infection (COVID-19) of a Mild or Asymptomatic Course

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. The rapid spread of COVID-19 in the world, the severity of disease, high morbidity and mortality have rightly made the COVID-19 pandemic a major threat to humanity. Therefore, one of the most urgent problems for practical health care is the issue of development of immunity for COVID-19 survivors, the possibility of re-infection, and the appropriateness of vaccination. The article presents the interim results of the study was named “RESPONSE” devoted to assessing the immunity for 90 days from patients that survived COVID-19 in a mild or asymptomatic course. 

Aims — to study of the dynamics of generation of SARS-CoV-2 adhesive (S) protein neutralizing antibodies (IgG) and specificities of humoral immunity from COVID-19 survivors with light and asymptomatic form of disease in depending on gender and age. 

Materials and methods. Joint study by the Military Medical Academy n.a. S.M. Kirov and Laboratory Service “Helix” is being undertaken in the period from January 06, 2020 to August 1, 2021 on the basis of Academy clinics and Helix diagnostic centers in Saint Petersburg. The study was included 1109 males and females aged 18 to 70 (average age 38.2), who received to outpatient treatment of light and asymptomatic form of New Coronavirus Infection. All patients included in the investigation were done survey of quantitative neutralizing antibodies of class IgG to S-protein SARS-CoV-2 content in venous blood in 30, 45, 60 and 90 days from the last result of positive polymerase chain reaction with reverse transcription (OT-PCR) for determining nucleic acid SARS-CoV-2 in biological material by immunochemiluminescent analysis (LIAISON XL, DiaSorin S.p.A., made in Italy). 

Results. The IgG class antibody to the S-protein SARS-CoV-2 were not diagnosed 30 days after the survived infection only 0.9% of young women (18–44 years) and 0.8% of men in the same age bracket. In other age groups, antibodies were defined in all participants of study. Titer of IgG gradually increases to peak concentration after 45 days, it’s kept at this level to the 60th day, and then it has a decreasing trend after 90 days from the onset of the disease. 

Conclusions. The results show the timing of generation and duration of the humoral response in survived patients COVID-19 in a mild or asymptomatic form. For 45 days, antibodies were determined in all participants of the study, reflecting the development of post-infectious humoral immunity, which was maintained in patients with the mild or asymptomatic forms of COVID-19 at least 3 months.

Full Text

Restricted Access

About the authors

Evgeniy V. Kryukov

Military Medical Academy named after S.M. Kirov

Email: evgeniy.md@mail.ru
ORCID iD: 0000-0002-8396-1936
SPIN-code: 3900-3441

MD, PhD, Professor, Corresponding Member of the RAS

Russian Federation, 6, Akademika Lebedeva str., 194044, St. Petersburg

Dmitriy V. Trishkin

The Main Military Medical Directorate

Email: vmeda-nio@mil.ru
SPIN-code: 1082-0719


Russian Federation, Moscow

Vladimir V. Salukhov

Military Medical Academy named after S.M. Kirov

Author for correspondence.
Email: vlasaluk@yandex.ru
ORCID iD: 0000-0003-1851-0941
SPIN-code: 4531-6011


Russian Federation, 6, Akademika Lebedeva str., 194044, St. Petersburg

Pavel S. Sadovnikov

Laboratory Service “Helix”

Email: sadovnikov.p@helix.ru
ORCID iD: 0000-0002-6022-5709
SPIN-code: 1542-2836
Russian Federation, St. Petersburg

Yuriy V. Andreychuk

Laboratory Service “Helix”

Email: andreychuk.y@helix.ru
ORCID iD: 0000-0003-2016-8815
Russian Federation, St. Petersburg

Alexander A. Chugunov

Military Medical Academy named after S.M. Kirov

Email: alexandrchugun@yandex.ru
ORCID iD: 0000-0002-2532-6133
SPIN-code: 3839-7619


Russian Federation, 6, Akademika Lebedeva str., 194044, St. Petersburg

Bogdan N. Kotiv

Military Medical Academy named after S.M. Kirov

Email: kotivbn@gmail.com
ORCID iD: 0000-0001-7537-1218
SPIN-code: 4038-0855

MD, PhD, Professor

Russian Federation, 6, Akademika Lebedeva str., 194044, St. Petersburg


  1. WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed: 10.07.2020).
  2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: https://doi.org/10.1038/s41586-020-2012-7
  3. Kang HYJ, Wang YS, Tong ZH. Personal knowledge on novel coronavirus pneumonia. Chin Med J (Engl). 2020;(133):1121–1122. doi: https://doi.org/10.1097/cm9.0000000000000757
  4. Coronavirus Disease (COVID-19) Situation Reports. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed: 10.07.2020).
  5. Sfera A, Osorio C, Jafri N, et al. Intoxication with Endogenous Angiotensin II: A COVID-19 Hypothesis. Front Immunol. 2020;11:1472. doi: https://doi.org/10.3389/fimmu.2020.01472
  6. Салухов В.В., Гуляев Н.И., Дорохина Е.В. Оценка системных воспалительных реакций и коагулопатии на фоне гормональной терапии при ковид-ассоциированном поражении легких // Медицинский совет. — 2020. — № 21. — С. 230–237. [Salukhov VV, Gulyaev NI, Dorokhina EV. Assessment of systemic inflammatory reactions and coagulopathy against the background of hormonal therapy in covid-associated lung damage. Meditsinskiy sovet = Medical Council. 2020;(21):230–237. (In Russ.)] doi: https://doi.org/10.21518/2079-701X-2020-21-230-237
  7. Yong G, Yi Y, Tuantuan L, et al. Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2). J Med Virol. 2020;92(10):1975–1979. doi: https://doi.org/10.1002/jmv.25919
  8. Xie J, Ding C, Li J, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol. 2020;92(10):2004–2010. doi: https://doi.org/10.1002/jmv.25930
  9. McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020;5 (18):e142386. doi: https://doi.org/10.1172/jci.insight.142386
  10. Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi: https://doi.org/10.1101/2020.09.06.20189480
  11. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791–797. doi: https://doi.org/10.1099/jgv.0.001439
  12. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020;323(22):2245–2246. doi: https://doi.org/10.1001/jama.2020.7869
  13. Салухов В.В., Харитонов М.А., Крюков Е.В., и др. Актуальные вопросы диагностики, обследования и лечения больных с COVID-19-ассоциированной пневмонией в различных странах и континентах // Медицинский совет. — 2020. — № 21. — С. 96–102. [Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Meditsinskiy sovet = Medical Council. 2020;(21):96–102. (In Russ.)] doi: https://doi.org/10.21518/2079-701X-2020-21-96-102
  14. Зайцев А.А., Голухова Е.З., Мамалыга М.Л., и др. Эффективность пульс-терапии метилпреднизолоном у пациентов с СOVID-19 // Клиническая микробиология и антимикробная химиотерапия. — 2020. — Т. 22. — № 2. — С. 88–89. [Zaitsev AA, Golukhova EZ, Mamalyga ML, et al. Efficacy of methylprednisolone pulse therapy in patients with COVID-19. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(2):88–89. (In Russ.)]
  15. Чугунов А.А., Салухов В.В., Данцева О.В., и др. Некоторые аспекты применения глюкокортикоидных препаратов в комплексном лечении новой коронавирусной инфекции // Медицинский альянс. — 2021. — Т. 9. — № 1. — С. 43–51. [Chugunov АA, Salukhov VV, Dantseva ОV, Kharitonov МA, et al. Some aspects of application glucocorticoid drugs in the complex treatment of new coronaviral infection. Medical Alliance. 2021;9(1):43–51. (In Russ.)] doi: https://doi.org/10.36422/23076348-2021-9-1-43-51
  16. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734. doi: https://doi.org/10.1056/nejmoa2006100
  17. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437–442. doi: https://doi.org/10.1038/s41586-020-2456-9
  18. Lau CS, Oh HML, Hoo SP, et al. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta. 2020;510:760–766. doi: https://doi.org/10.1016/j.cca.2020.09.005
  19. World report on ageing and health. World Health Organization, Geneva, Switzerland;2015. 246 p. Available from: https://apps.who.int/iris/handle/10665/186463
  20. Bag Soytas R, Cengiz M, Islamoglu MS, et al. Does the COVID-19 seroconversion in older adults resemble the young? J Med Virol. 2021;93(10):5777–5782. doi: https://doi.org/10.1002/jmv.27106
  21. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577–599. doi: https://doi.org/10.1146/annurev-cellbio-100616-060718
  22. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638. doi: https://doi.org/10.1038/nri.2016.90
  23. Fink AL, Engle K, Ursin RL, et al. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci USA. 2018;115(49):12477–12482. doi: https://doi.org/10.1073/pnas.1805268115
  24. Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci USA. 2014;111(2):869–874. doi: https://doi.org/10.1073/pnas.1321060111
  25. Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–1163. doi: https://doi.org/10.1056/NEJMc070348

Supplementary files

Supplementary Files
1. Fig. 1. Dynamics of antibody production depending on age and gender

Download (232KB)

Copyright (c) 2021 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies